Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Neurological conditions

Drug interaction may explain cannabidiol’s effects on severe form of epilepsy

Findings from research on drop-seizure frequency in patients with Lennox-Gastaut syndrome have suggested an increase in N-desmethylclobazam exposure may explain the reduction in seizure frequency.

Clobazam blister pack

Source: Science Photo Library

In a clinical trial simulation, patients taking 10mg or 20mg clobazam were assumed to have a two- to seven-fold increase in N-desmethylclobazam exposure

A drug–drug interaction between cannabidiol and anti-epileptic drug clobazam may explain why cannabidiol reduces the frequency of seizures in patients with a severe form of epilepsy, researchers have reported in the British Journal of Clinical Pharmacology (28 October 2019)[1].

The research team used clinical trial simulations to investigate the effect of cannabidiol 20mg/kg/day on drop-seizure frequency in patients with Lennox-Gastaut syndrome.

Using population-pharmacokinetic models, the researchers simulated the GWPCARE3 trial — one of the trials that led the US Food and Drug Administration to approve the use of cannabidiol as an anti-epileptic drug.

In the simulation, patients taking 10mg or 20mg clobazam were assumed to have a two- to seven-fold increase in N-desmethylclobazam exposure.

Findings from the simulation suggest that the effect of cannabidiol on the reduction in seizure frequency observed in previous clinical trials may be explained by a six-fold increase in N-desmethylclobazam exposure, which occurs when patients are treated with both 20mg clobazam and cannabidiol.

Geert Jan Groeneveld, chief scientific and medical officer at the Centre for Human Drug Research in Leiden, the Netherlands, said: “The effects of cannabidiol on seizure frequency in Lennox-Gastaut patients could be explained entirely through estimated elevations of blood levels of clobazam, which might mean that cannabidiol in itself may not have any, or at best limited, anti-epileptic effects.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2020.20207605

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Sport and Exercise Medicine for Pharmacists

    Sport and Exercise Medicine for Pharmacists

    All the information you need to provide patients with evidence-based advice on sports and exercise related health matters.

    £27.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.